tbuckley/cabot-search huggingface dataset:
Abstract ES11-2: Macro and Micro: Macrophage and microbiome diversity in the breast cancer microenvironment
Authors: JL Guerriero
Journal: Cancer Research (2022)

Abstract The breast tumor microenvironment (TME), devoid of nutrients and oxygen, recruits tumor associated macrophages (TAMs) that promote angiogenesis, metastasis and tumor growth. Removal or conversion of TAMs to an anti-tumor phenotype enhances chemo- and immuno-therapy in pre-clinical models and establishes TAMs as targets for anti-cancer therapy. Translation to the clinic has been slow, likely because current strategies broadly target macrophages. Several subsets of TAMs have been identified, yet little is known about their subset diversity in breast cancer and response to therapy. The failure to characterize TAM subsets has likely hindered progress in therapeutic targeting. This educational talk will provide a broad overview of the diversity of TAMs as well as the microbiome and how they are potentially intertwined within the complex breast TME. The talk will incorporate the state of the field to include elucidating the complexity of TAMs in breast cancer including their ontogeny, tissue specificity, phenotype, subset diversity and spatial relationship within the breast tumor. In addition, how the tumor microbiome may influence myeloid function and phenotype will be explored. Citation Format: JL Guerriero. Macro and Micro: Macrophage and microbiome diversity in the breast cancer microenvironment [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr ES11-2.
Health‐related quality of life in patients with <scp>light chain</scp> amyloidosis treated with bortezomib, cyclophosphamide, and dexamethasone ± daratumumab: Results from the <scp>ANDROMEDA</scp> study
Authors: Vaishali Sanchorawala, Giovanni Palladini, Monique C. Minnema, Arnaud Jaccard, Hans C. Lee, Simon Gibbs, Peter Mollee, Christopher Venner, Jin Lu, Stefan Schönland, Moshe Gatt, Kenshi Suzuki, Kihyun Kim, María Teresa Cibeira, Meral Beksac, Edward Libby, Jason Valent, Vania Hungria, Sandy W. Wong, Michael Rosenzweig, Naresh Bumma, Dominique Chauveau, Katharine S. Gries, John Fastenau, Nam Phuong Tran, Xiang Qin, Sandra Y. Vasey, Brendan M. Weiss, Jessica Vermeulen, Kai Fai Ho, Giampaolo Merlini, Raymond L. Comenzo, Efstathios Kastritis, Ashutosh D. Wechalekar
Journal: American Journal of Hematology (2022)

In the phase 3 ANDROMEDA trial, patients treated with daratumumab, bortezomib, cyclophosphamide, and dexamethasone (D-VCd) had significantly higher rates of organ and hematologic response compared with patients who received VCd alone. Here, we present patient-reported outcomes (PROs) from the ANDROMEDA trial. PROs were assessed through cycle 6 using three standardized questionnaires. Treatment effect through cycle 6 was measured by a repeated-measures, mixed-effects model. The magnitude of changes in PROs versus baseline was generally low, but between-group differences favored the D-VCd group. Results were generally consistent irrespective of hematologic, cardiac, or renal responses. More patients in the D-VCd group experienced meaningful improvements in PROs; median time to improvement was more rapid in the D-VCd group versus the VCd group. After cycle 6, patients in the D-VCd group received daratumumab monotherapy and their PRO assessments continued, with improvements in health-related quality of life (HRQoL) reported through cycle 19. PROs of subgroups with renal and cardiac involvement were consistent with those of the intent-to-treat population. These results demonstrate that the previously reported clinical benefits of D-VCd were achieved without decrement to patients' HRQoL and provide support of D-VCd in patients with AL amyloidosis.
EFFICACY AND SAFETY OF EARLY LIPID LOWERING TREATMENT IN CHILDREN WITH FAMILIAL HYPERCHOLESTEROLEMIA
Authors: Fabiana Cordeiro Juliani, Marcio Hiroshi Miname, Maria Helane Costa Gurgel Castelo, Ana Paula Marte Chacra, Wilson Salgado, Elaine dos Reis Coutinho, Cinthia Elim Jannes, Alexandre Pereira, Jose Eduardo Krieger, Raul Cavalcante Maranhao, Raul Santos, Viviane Zorzanelli Rocha
Journal: Journal of the American College of Cardiology (2022)
Preadmission use of antidiabetic medications and mortality among patients with COVID-19 having type 2 diabetes: A meta-analysis
Authors: Nam Nhat Nguyen, Dung Si Ho, Hung Song Nguyen, Dang Khanh Ngan Ho, Hung-Yuan Li, Chia-Yuan Lin, Hsiao-Yean Chiu, Yang-Ching Chen
Journal: Metabolism (2022)
Endoscopy International Open – recently published
Journal: Endoscopy (2022)

Comment on: Individualized feedback on colonoscopy skills improves group colonoscopy quality in providers with lower adenoma detection ratesEndosc Int Open 2022; 10(03): E232-E237DOI: 10.1055/a-1529-5574 Comment on: Optimal timing of rectal diclofenac in preventing post-endoscopic retrograde cholangiopancreatography pancreatitisEndosc Int Open 2022; 10(03): E246-E253DOI: 10.1055/a-1675-2108 Comment on: Automatic detection of tumor vessels in indeterminate biliary strictures in digital single-operator cholangioscopyEndosc Int Open 2022; 10(03): E262-E268DOI: 10.1055/a-1723-3369
Dntt expression reveals developmental hierarchy and lineage specification of hematopoietic progenitors
Authors: Fabian Klein, Julien Roux, Grozdan Cvijetic, Patrick Fernandes Rodrigues, Lilly von Muenchow, Ruth Lubin, Pawel Pelczar, Simon Yona, Panagiotis Tsapogas, Roxane Tussiwand
Journal: Nature Immunology (2022)
DIFFERENCES IN ATRIAL FIBRILLATION OCCURRENCE AMONG YOUNG WOMEN WITH AND WITHOUT PERIPARTUM CARDIOMYOPATHY
Authors: Andrea C. Morales Lara, Erika J. Douglass, Sina O’Sullivan, Patrick W. Johnson, Mohamad H. Yamani, Demilade Adedinsewo
Journal: Journal of the American College of Cardiology (2022)
VENTRICULAR SEPTAL PERFORATION IN THE SETTING OF TAKOTSUBO SYNDROME: LEARNING HOW TO IMPROVE MORTALITY RATE THROUGH EARLY RECOGNITION
Authors: Tai Thien Tan Tri Truyen, Hai Dang, San Tran, Phuc Vu, Trang Thi Bich Le, Hai Duong Nguyen, Dinh Nhat Truong, Huong Tran, Doan Ngoc Chau Nguyen, Hoang Nhat Pham, Amandeep Goyal, Khiem Ngo, Phillip Tran
Journal: Journal of the American College of Cardiology (2022)
The impact of secondary infections in COVID-19 critically ill patients
Authors: Federica Murgia, Maura Fiamma, Silvia Serra, Sabrina Olla, Maria Cristina Garau, Eleonora Cocco, Lorena Lorefice, Sandro Muntoni, Peppino Paffi, Stefano Porru, Marta Abis, Gabriele Finco, Saverio Bellizzi, Orietta Massidda, Franco Carta, Luigi Atzori
Journal: Journal of Infection (2022)
Redoubling efforts to sustain seasonal malaria chemoprevention
Authors: Perpetua Uhomoibhi, Keziah Laurencia Malm, Idrissa Cisse, Hamza Dzibo, Abena Poku-Awuku, André-Marie Tchouatieu, Peter Ehizibue Olumese, Suzanne Van Hulle, Lia Florey, Scott Filler, Jaya Banerji
Journal: The Lancet Child & Adolescent Health (2022)
Drug Repurposing to Target Neuroinflammation and Sensory Neuron-Dependent Pain
Authors: Marco Sisignano, Philip Gribbon, Gerd Geisslinger
Journal: Drugs (2022)

Around 20% of the American population have chronic pain and estimates in other Western countries report similar numbers. This represents a major challenge for global health care systems. Additional problems for the treatment of chronic and persistent pain are the comparably low efficacy of existing therapies, the failure to translate effects observed in preclinical pain models to human patients and related setbacks in clinical trials from previous attempts to develop novel analgesics. Drug repurposing offers an alternative approach to identify novel analgesics as it can bypass various steps of classical drug development. In recent years, several approved drugs were attributed analgesic properties. Here, we review available data and discuss recent findings suggesting that the approved drugs minocycline, fingolimod, pioglitazone, nilotinib, telmisartan, and others, which were originally developed for the treatment of different pathologies, can have analgesic, antihyperalgesic, or neuroprotective effects in preclinical and clinical models of inflammatory or neuropathic pain. For our analysis, we subdivide the drugs into substances that can target neuroinflammation or substances that can act on peripheral sensory neurons, and highlight the proposed mechanisms. Finally, we discuss the merits and challenges of drug repurposing for the development of novel analgesics.
Increasing generalizability via the principle of minimum description length
Authors: Wes Bonifay
Journal: Behavioral and Brain Sciences (2022)

Traditional statistical model evaluation typically relies on goodness-of-fit testing and quantifying model complexity by counting parameters. Both of these practices may result in overfitting and have thereby contributed to the generalizability crisis. The information-theoretic principle of minimum description length addresses both of these concerns by filtering noise from the observed data and consequently increasing generalizability to unseen data.
Abstract ES2-1: Everything you always wanted to know about AI but were afraid to ask
Authors: R Barzilay
Journal: Cancer Research (2022)

Abstract In this talk, I will introduce the audience to the foundations of artificial intelligence and its application to breast cancer diagnostics and care. By nature, many of the traditional clinical tasks such as risk assessment, prediction of treatment efficacy and forecasting patient trajectory can be thought of as prediction problems. Given sufficient amounts of patient data with outcomes, a machine learning model can make predictions which often exceed in accuracy human experts. However, to make these tools more applicable in the clinical setting, we need to augment AI models with the ability to explain their decisions to humans, and assess their uncertainty. In my talk, I will give multiple examples of deployed AI applications, analyzing their strengths and weaknesses. First, I will describe a natural language processing system for extracting tumor information from pathology reports. Next, I will talk about image-based AI models for risk assessment and early detection of breast cancer. Finally, I will summarize AI drug discovery methods for personalized medicine. Citation Format: R Barzilay. Everything you always wanted to know about AI but were afraid to ask [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr ES2-1.
Intra-articular Platelet-Rich Plasma vs Placebo Injection and Pain and Medial Tibial Cartilage Volume in Patients With Knee Osteoarthritis
Authors: Michael R. Baria, David C. Flanigan
Journal: JAMA (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
OUTPATIENT HEART FAILURE MONITORING WITH A NOVEL CARDIAC SCALE: TRACKING VOLUME STATUS
Authors: Melissa Ramos, Reid Goodman, Daniel A. Aldea, Mateen Saffarian, Preeti Singhal, Daniel J. Miklin, Philip Kingsford, Janice Kwong, Lena Onaka, Sarin Patel, Corey Centen, Sarah Smith, Daniel Yazdi, Michael W. Fong
Journal: Journal of the American College of Cardiology (2022)
Methods for the identification and characterization of extracellular vesicles in cardiovascular studies: from exosomes to microvesicles
Authors: Sean M Davidson, Chantal M Boulanger, Elena Aikawa, Lina Badimon, Lucio Barile, Christoph J Binder, Alain Brisson, Edit Buzas, Costanza Emanueli, Felix Jansen, Miroslava Katsur, Romaric Lacroix, Sai Kiang Lim, Nigel Mackman, Manuel Mayr, Philippe Menasché, Rienk Nieuwland, Susmita Sahoo, Kaloyan Takov, Thomas Thum, Pieter Vader, Marca H M Wauben, Kenneth Witwer, Joost P G Sluijter
Journal: Cardiovascular Research (2022)

Abstract Extracellular vesicles (EVs) are nanosized vesicles with a lipid bilayer that are released from cells of the cardiovascular system, and are considered important mediators of intercellular and extracellular communications. Two types of EVs of particular interest are exosomes and microvesicles, which have been identified in all tissue and body fluids and carry a variety of molecules including RNAs, proteins, and lipids. EVs have potential for use in the diagnosis and prognosis of cardiovascular diseases and as new therapeutic agents, particularly in the setting of myocardial infarction and heart failure. Despite their promise, technical challenges related to their small size make it challenging to accurately identify and characterize them, and to study EV-mediated processes. Here, we aim to provide the reader with an overview of the techniques and technologies available for the separation and characterization of EVs from different sources. Methods for determining the protein, RNA, and lipid content of EVs are discussed. The aim of this document is to provide guidance on critical methodological issues and highlight key points for consideration for the investigation of EVs in cardiovascular studies.
Histone methyltransferase WHSC1 loss dampens MHC-I antigen presentation pathway to impair IFN-γ–stimulated antitumor immunity
Authors: Jiale Ren, Ni Li, Siyu Pei, Yannan Lian, Li Li, Yuchong Peng, Qiuli Liu, Jiacheng Guo, Xuege Wang, Ying Han, Guoying Zhang, Hanling Wang, Yaqi Li, Jun Jiang, Qintong Li, Minjia Tan, Junjie Peng, Guohong Hu, Yichuan Xiao, Xiong Li, Moubin Lin, Jun Qin
Journal: Journal of Clinical Investigation (2022)

IFN-γ–stimulated MHC class I (MHC-I) antigen presentation underlies the core of antitumor immunity. However, sustained IFN-γ signaling also enhances the programmed death ligand 1 (PD-L1) checkpoint pathway to dampen antitumor immunity. It remains unclear how these opposing effects of IFN-γ are regulated. Here, we report that loss of the histone dimethyltransferase WHSC1 impaired the antitumor effect of IFN-γ signaling by transcriptional downregulation of the MHC-I machinery without affecting PD-L1 expression in colorectal cancer (CRC) cells. Whsc1 loss promoted tumorigenesis via a non-cell-autonomous mechanism in an Apcmin/+ mouse model, CRC organoids, and xenografts. Mechanistically, we found that the IFN-γ/STAT1 signaling axis stimulated WHSC1 expression and, in turn, that WHSC1 directly interacted with NLRC5 to promote MHC-I gene expression, but not that of PD-L1. Concordantly, silencing Whsc1 diminished MHC-I levels, impaired antitumor immunity, and blunted the effect of immune checkpoint blockade. Patient cohort analysis revealed that WHSC1 expression positively correlated with enhanced MHC-I expression, tumor-infiltrating T cells, and favorable disease outcomes. Together, our findings establish a tumor-suppressive function of WHSC1 that relays IFN-γ signaling to promote antigen presentation on CRC cells and provide a rationale for boosting WHSC1 activity in immunotherapy.
PERK reprograms hematopoietic progenitor cells to direct tumor-promoting myelopoiesis in the spleen
Authors: Mingyu Liu, Chong Wu, Shufeng Luo, Qiaomin Hua, Hai-Tian Chen, Yulan Weng, Junyu Xu, Huiling Lin, Lu Wang, Jinheng Li, Lan Zhu, Zhenhong Guo, Shi-Mei Zhuang, Tiebang Kang, Limin Zheng
Journal: The Journal of Experimental Medicine (2022)

The spleen is an important site of hematopoietic stem/progenitor cell (HSPC) preconditioning and tumor-promoting myeloid cell generation in cancer, but the regulatory mechanism remains unclear. Here, we found that PKR-like endoplasmic reticulum kinase (PERK) mediated HSPC reprogramming into committed MDSC precursors in the spleen via PERK–ATF4–C/EBPβ signaling. Pharmacological and genetic inhibition of this pathway in murine and human HSPCs prevented their myeloid descendant cells from becoming MDSCs even with subsequent exposure to tumor microenvironment (TME) factors. In mice, the selective delivery of PERK antagonists to the spleen was not only sufficient but more effective than the tumor-targeted strategy in preventing MDSC activation in the tumor, leading to profound TME reshaping and tumor regression. Clinically, HSPCs in the spleen of cancer patients exhibit increased PERK signaling correlated with enhanced myelopoiesis. Our findings indicate that PERK-mediated HSPC preconditioning plays a crucial role in MDSC generation, suggesting novel spleen-targeting therapeutic opportunities for restraining the tumor-promoting myeloid response at its source.
CGE22-101: Dynamically Accumulating Homologous Recombination Deficiency (HRD) Status Served as an Important Prognosis Factor in High-Grade Serous Ovarian Cancer
Authors: Rongjia Su, Yuan Liu, Xiaomei Wu, Jiangdong Xiang, Xiaowei Xi
Journal: Journal of the National Comprehensive Cancer Network (2022)

"CGE22-101: Dynamically Accumulating Homologous Recombination Deficiency (HRD) Status Served as an Important Prognosis Factor in High-Grade Serous Ovarian Cancer" published on 31 Mar 2022 by National Comprehensive Cancer Network.
Inappropriate use of ivermectin during the COVID-19 pandemic: primum non nocere!
Authors: Aleksandra Barac, Michele Bartoletti, Ozlem Azap, Linda Bussini, Onder Ergonul, Robert Krause, José Ramón Paño-Pardo, Nicholas R. Power, Jesús Rodríguez-Baño, Marcella Sibani, Balint Gergely Szabo, Sotirios Tsiodras, Paul E. Verweij, Alejandro Martín Quirós, Ines Zollner-Schwetz
Journal: Clinical Microbiology and Infection (2022)
Sulopenem: An Intravenous and Oral Penem for the Treatment of Urinary Tract Infections Due to Multidrug-Resistant Bacteria
Authors: George G. Zhanel, Marianna Pozdirca, Alyssa R. Golden, Courtney K. Lawrence, Sheryl Zelenitsky, Liam Berry, Frank Schweizer, Denice Bay, Heather Adam, Michael A. Zhanel, Philippe Lagacé-Wiens, Andrew Walkty, Neal Irfan, Kurt Naber, Joseph P. Lynch, James A. Karlowsky
Journal: Drugs (2022)
“IS THE COVERAGE AREA OF THE SECOND GENERATION TRANSCATHETER AORTIC VALVE REPLACEMENT EMBOLIC PROTECTION DEVICES TOO GENEROUS”?
Authors: Muhammad Khakwani, Sumit Sohal, Mihir Barvalia, Isha Samreen, Rajiv Tayal, Sergio Waxman, Najam Wasty
Journal: Journal of the American College of Cardiology (2022)
Precision medicine in pediatric severe asthma: Targeted blockade of type 2 inflammation
Authors: Allyson S. Larkin, Sally E. Wenzel
Journal: Cell Reports Medicine (2022)

A study by Bacharier et al. demonstrated that children with uncontrolled moderate-to-severe asthma with elevated type 2 biomarkers who received dupilumab had fewer exacerbations and better lung function.1 These results highlight precision medicine approaches in pediatric asthma.
Strengthening global health security by improving disease surveillance in remote rural areas of low-income and middle-income countries
Authors: Katherine E L Worsley-Tonks, Jeff B Bender, Sharon L Deem, Adam W Ferguson, Eric M Fèvre, Dino J Martins, Dishon M Muloi, Suzan Murray, Mathew Mutinda, Darcy Ogada, George P Omondi, Shailendra Prasad, Hannah Wild, Dawn M Zimmerman, James M Hassell
Journal: The Lancet Global Health (2022)

The COVID-19 pandemic has underscored the need to strengthen national surveillance systems to protect a globally connected world. In low-income and middle-income countries, zoonotic disease surveillance has advanced considerably in the past two decades. However, surveillance efforts often prioritise urban and adjacent rural communities. Communities in remote rural areas have had far less support despite having routine exposure to zoonotic diseases due to frequent contact with domestic and wild animals, and restricted access to health care. Limited disease surveillance in remote rural areas is a crucial gap in global health security. Although this point has been made in the past, practical solutions on how to implement surveillance efficiently in these resource-limited and logistically challenging settings have yet to be discussed. We highlight why investing in disease surveillance in remote rural areas of low-income and middle-income countries will benefit the global community and review current approaches. Using semi-arid regions in Kenya as a case study, we provide a practical approach by which surveillance in remote rural areas can be strengthened and integrated into existing systems. This Viewpoint represents a transition from simply highlighting the need for a more holistic approach to disease surveillance to a solid plan for how this outcome might be achieved.
Secreted phospholipase A2 modifies extracellular vesicles and accelerates B cell lymphoma
Authors: Kai Kudo, Yoshimi Miki, Joaquim Carreras, Shunya Nakayama, Yasushi Nakamoto, Masatoshi Ito, Etsuko Nagashima, Kei Yamamoto, Hiroshi Higuchi, Shin-Ya Morita, Asuka Inoue, Junken Aoki, Kiyoshi Ando, Naoya Nakamura, Makoto Murakami, Ai Kotani
Journal: Cell Metabolism (2022)
“The Future Independence and Progress of American Medicine in the Age of Chemistry”
Journal: JAMA (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal